Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer

Former Danaher Executive Further Strengthens Senior Management Team

/EIN News/ -- SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the appointment of Betsy Jensen as Chief Human Resources Officer. Jensen will lead Standard BioTools™ human resources function and will report to President and Chief Executive Officer Michael Egholm, PhD.

An essential element of Standard BioTools strategy and transformation is a

commitment to strengthening the senior management team with seasoned operators to support the company’s high growth expectations and drive to profitability.

Jensen was most recently Chief Human Resources Officer at Gibraltar a position she held since March 2021. Previously, she spent nearly eight years leading human resources and internal communications at several Danaher subsidiaries including Hach, Cepheid, Molecular Devices and SCIEX. Throughout her career, Betsy has partnered with businesses to accelerate growth, embrace continuous improvement, provide leadership and develop strategy and analytics to drive change and advance innovation. Betsy holds a BS in Business Management with a concentration in Human Resources from San Jose State University.

“Standard BioTools’ people and culture are the critical components of our success toward building out the platform we are developing and driving our long-term strategic advantage,” said Egholm. “Hiring, developing and retaining talent are key to our success, and with Betsy’s experience scaling and building high-performance teams, I am confident we will grow our team with the industry’s best talent.”

“In today’s competitive environment, leadership, culture and core values are what set apart great organizations from the rest,” said Jensen. “It’s clear Standard BioTools’ team of talented and seasoned operators is building an exceptional company that will be the next great provider of solutions to researchers around the world. I am excited to be joining Standard BioTools as it continues to execute on this mission.”

About Standard BioTools Inc. 

Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo and “Unleashing tools to accelerate breakthroughs in human health” are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Available Information 

Standard BioTools uses its website (standardbio.com), investor site (investors.standardbio.com), corporate Twitter account (@Standard_BioT), Facebook page (facebook.com/StandardBioT), and LinkedIn page (linkedin.com/company/standard-biotools) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and Standard BioTools may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools’ website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts.